These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 8992327)
61. Letter by Lowenthal et al regarding article, "BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial". Lowenthal A; Shah A; Bernstein HS Circ Heart Fail; 2010 Nov; 3(6):e32; author reply e33. PubMed ID: 21081737 [No Abstract] [Full Text] [Related]
62. Special considerations for carvedilol use in heart failure. Yancy CW Am J Cardiol; 2004 May; 93(9A):64B-8B. PubMed ID: 15144941 [TBL] [Abstract][Full Text] [Related]
63. [Beta blocker for therapy of heart failure. Decreased mortality and fewer clinic admissions]. Pickl S Fortschr Med; 1997 Apr; 115(11):22. PubMed ID: 9221239 [No Abstract] [Full Text] [Related]
64. Carvedilol--a wide therapeutic potential in cardiovascular syndromes. Introduction. Taylor SH; Storstein L Cardiology; 1993; 82 Suppl 3():1-2. PubMed ID: 8106157 [No Abstract] [Full Text] [Related]
65. Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. de Boer RA; Siebelink HJ; Tio RA; Boomsma F; van Veldhuisen DJ Eur J Heart Fail; 2001 Jun; 3(3):331-3. PubMed ID: 11378004 [No Abstract] [Full Text] [Related]
66. The COHERE Registry: hype or hope? Ghali JK J Card Fail; 2000 Sep; 6(3):272-5. PubMed ID: 10997755 [No Abstract] [Full Text] [Related]
67. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419 [TBL] [Abstract][Full Text] [Related]
75. Role of carvedilol in atrial fibrillation: insights from clinical trials. Gheorghiade M; Lukas MA Am J Cardiol; 2004 May; 93(9A):53B-7B. PubMed ID: 15144939 [TBL] [Abstract][Full Text] [Related]
76. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial. Bauman JL; Talbert RL J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248 [TBL] [Abstract][Full Text] [Related]
77. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life? Fowler MB Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708 [TBL] [Abstract][Full Text] [Related]
78. [Place of beta blockaders in the treatment of heart failure]. Pornin M; Van Viet H Ann Cardiol Angeiol (Paris); 1998 Dec; 47(10):753-6. PubMed ID: 9922855 [No Abstract] [Full Text] [Related]
79. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure. Hauptman PJ; Pressler SJ; Sackner-Bernstein J; Ordronneau P; Udelson JE; Am J Cardiol; 2006 Oct; 98(7A):60L-66L. PubMed ID: 17023234 [TBL] [Abstract][Full Text] [Related]
80. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]